01 Delivery Function
Payload protection
Formulations can be tuned for selected therapeutic payloads, including peptides, biologics, and nucleic-acid-based approaches where program data support the pairing.
Proprietary LNP Drug Delivery Platform
Advanced LNP is an enabling formulation platform for selected payload, route, and tissue-access needs. It is not the primary antiviral mechanism of the pipeline.
Payload Protection, Targeting, and Controlled Release
Advanced LNP may support payload protection, tissue targeting, controlled release, residence, and uptake when formulation creates a clear development advantage.
02 Delivery Function
Targeting and tissue access
Evaluation may include pulmonary, lymphoid, mucosal, central nervous system, or difficult-barrier contexts depending on the intended route and payload.
03 Delivery Function
Controlled release and uptake
Residence time, uptake behavior, and local exposure are evaluated formulation by formulation for the intended site of action.
Blood–Brain Barrier and Central Nervous System Transport
Research-stage materials support continued evaluation of LNP delivery concepts for difficult biological barriers, including blood–brain barrier access and central nervous system transport.
These studies are presented as delivery rationale, not as Macro HRD clinical milestones.
In vivo Analysis
Multi-photon microscope
EB measurements in CSF
lipid Evans blue
Lung and Spleen Targeting Data
Research-stage LNP formulation work supports organ-directed delivery across selected tissue contexts, providing preclinical rationale for continued platform development.
In Vivo Imaging
Ex Vivo Imaging
Lung-
targeting
LNP
Spleen-
targeting
LNP
Preclinical Imaging / Biodistribution
Lung-targeting LNP
Research-stage materials describe LNP variants optimized for pulmonary targeting in lung-directed contexts.
Preclinical Imaging / Biodistribution
Spleen-targeting LNP
Research-stage materials describe spleen-targeting LNP behavior relevant to lymphoid delivery and immune-compartment access.
Organ-directed Delivery
Selected tissue contexts
Delivery behavior is evaluated by formulation, route, payload, and intended tissue-access need.
Deliverability Evidence in Selected Models
Available in vitro and in vivo studies are used as delivery rationale for difficult target-cell and tissue contexts.
Delivery to Tough Target cells
Broader Therapeutic Potential
Although Macro HRD's public pipeline is focused on infectious disease, Advanced LNP may have broader relevance where formulation is a limiting factor.
Potential future applications may include central nervous system, barrier, organ-directed, mucosal, or local delivery contexts guided by future evidence.
HPV Topical
Potential formulation support for mucosal residence, epithelial localization, and local exposure in HPV-specific studies.
HIV Trispecific Antibody
Optional supportive delivery evaluation for reservoir-tissue access where formulation adds value.
Future Difficult-Tissue Delivery
Potential delivery applications in central nervous system, barrier, or organ-directed contexts guided by future evidence.
Related Programs and Technology Platforms
The platform may support AH-D Enveloped Viruses formulation, HIV Trispecific Antibody delivery evaluation, or HPV topical exploration where program data justify the pairing.